Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit in a phase I study of cabozantinib, which includ...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Kurzrock, Razelle, Sherman, Steven I., Ball, Douglas W., Forastiere, Arlene A., Cohen, Roger B., Mehra, Ranee, Pfister, David G., Cohen, Ezra E.W., Janisch, Linda, Nauling, Forlisa, Hong, David S., Ng, Chaan S., Ye, Lei, Gagel, Robert F., Frye, John, Müller, Thomas, Ratain, Mark J., Salgia, Ravi
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2011
Fag:
Original Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646303/
https://ncbi.nlm.nih.gov/pubmed/21606412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.4145
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker